共 50 条
Olfactory dysfunction among patients with COVID-19
被引:5
|作者:
Alkholaiwi, Feras M.
[1
]
Altamimi, Alhanouf F.
[2
,3
]
Almalki, Hanan H.
[2
]
Almughaiseeb, Fay A.
[2
]
Alsubaie, Shoug S.
[2
]
Alsayahi, Hessah S.
[4
]
Alhijli, Fras W.
[2
]
Alobaishi, Reema S.
[2
]
Agrawal, Amit
[6
]
Alqahtani, Zuhour A.
[5
]
Alotaibi, Fahad Z.
[1
]
机构:
[1] Imam Mohammad Ibn Saud Islamic Univ IMSIU, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Riyadh, Saudi Arabia
[2] Imam Mohammad Ibn Saud Islamic Univ IMSIU, Coll Med, Riyadh, Saudi Arabia
[3] Minist Natl Guard Hlth Affairs, King Abdulaziz Med City, Dept Family Med, Riyadh, Saudi Arabia
[4] King Fahad Med City, Dept Family Med, Riyadh, Saudi Arabia
[5] John Hopkins Aramco Healthcare, Dept Family Med, Dhahran, Eastern Provinc, Saudi Arabia
[6] Gandhi Med Coll, Dept Paediat, Bhopal, MP, India
关键词:
anosmia;
COVID-19;
Hyposmia;
olfactory dysfunction;
SARS-CoV-2;
CORONAVIRUS DISEASE 2019;
ANOSMIA;
SMELL;
D O I:
10.15537/smj.2023.44.11.20230264
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objectives: To assess the frequency of olfactory dysfunction (OD) among individuals afflicted with coronavirus disease of 2019 (COVID-19).Methods: A comprehensive literature search was carried out across several bibliographical databases (PubMed, Scopus, Google Scholar, and Web of Science) to extract publications in the English language between January 2020 and December 2021 to report the incidence of OD alone or together with gustatory dysfunction (GD) among COVID-19 patients.Results: Based on eligibility criteria, 84 articles were included from 27 countries, comprising 36,903 patients, of whom 58.1% were females. The generality rates of olfactory impairment alone was 34.60% and in conjunction with GD was 11.36%. Patients with OD were subclassified into various categories, and the prevalence of anosmia was 20.85%, 5.04% for hyposmia, 8.88% for anosmia or hyposmia, 1.84% for parosmia, 0.78% for phantosmia, and 0.02% for hyperosmia, among COVID-19 patients.Conclusion: Clinical features associated with OD, either isolated or in combination with GD, are common in patients with COVID-19 and consider important signs of COVID-19 that may guide clinicians in the early phase of the disease. PROSPERO Reg. No.: 417296
引用
收藏
页码:1085 / 1103
页数:19
相关论文